How to access Kesimpta from Saudi Arabia — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24

A Saudi patient with relapsing multiple sclerosis (MS) — including clinically isolated syndrome, relapsing-remitting, and active secondary-progressive disease — may receive a prescription for Kesimpta (ofatumumab) from their treating neurologist. Kesimpta is FDA-approved, developed by Novartis, and is a recognised subcutaneous anti-CD20 monoclonal antibody option for relapsing MS. In the Kingdom of Saudi Arabia, Kesimpta is not yet broadly registered for routine outpatient dispensing, and access is typically coordinated through the named-patient import pathway via the Saudi Food and Drug Authority (SFDA).

This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Kesimpta is a fully human anti-CD20 monoclonal antibody that depletes B cells. Unlike infusion-based anti-CD20 therapies, Kesimpta is self-administered at home as a subcutaneous injection using a prefilled Sensoready pen. The standard regimen is 20 mg at Weeks 0, 1, and 2 (loading doses), followed by 20 mg once every four weeks thereafter. The at-home dosing profile is a core reason many patients and neurologists select Kesimpta — it preserves patient mobility and reduces infusion-centre demand.

Eligibility requires a confirmed relapsing MS diagnosis per McDonald criteria, MRI evidence, and a rationale for anti-CD20 therapy. Before starting, your neurologist will screen for active or chronic hepatitis B (HBsAg and anti-HBc), verify vaccination status (updating live vaccines before depletion), baseline immunoglobulins, and screen for active infection. During therapy, IgG/IgM monitoring and infection surveillance continue.

Is Kesimpta legally importable into Saudi Arabia?

Yes — through the SFDA named-patient import framework. The mechanism permits a Saudi-licensed physician to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable for the patient, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented from the US source to the dispensing site. Saudi Arabia has a mature named-patient mechanism used routinely across MS and other chronic-therapy categories.

How the pathway works, step by step

1. Consultation with your treating neurologist. Confirmation of MS subtype, MRI review, prior DMT history, and clinical rationale for subcutaneous anti-CD20 therapy.
2. Pre-treatment screening. Hepatitis B panel, immunoglobulins, vaccination review and update, baseline infection screen.
3. SFDA named-patient application. The physician or hospital pharmacy files the application including clinical rationale, patient reference, product details, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Kesimpta from authorised distribution under DSCSA.
5. Cold-chain shipment. Kesimpta ships under validated 2–8 °C cold chain with continuous temperature logging and chain-of-custody documentation.
6. Arrival and first dose. The dispensing hospital pharmacy releases the loading-dose pens; the first injection is typically observed at the prescribing facility, with subsequent monthly doses self-administered at home.

What documentation your physician needs

• Clinical rationale letter confirming relapsing MS subtype and Kesimpta as the indicated therapy
• Verification of Saudi medical licence (SCFHS)
• MRI report supporting the diagnosis
• Hepatitis B screening results and vaccination history
• Baseline immunoglobulin levels
• Planned dosing calendar (Weeks 0, 1, 2 loading; monthly maintenance thereafter)
• Monitoring plan (IgG/IgM, infection surveillance)

Reserve Meds provides a physician documentation kit bundling templates SFDA reviewers expect for anti-CD20 MS named-patient imports.

Typical costs and indicative timing

Kesimpta's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 90,000–110,000 depending on the year and loading versus maintenance period. Cold-chain international logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative drug-only reference pricing, not guaranteed.

Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 7–14 days from the moment a complete SFDA application is submitted. Monthly refills, once the pathway is established, are generally faster.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A brief culturally-aware note: Ramadan and Hajj seasons can affect scheduling and refill timing. Our concierge team coordinates your monthly cycle with your family's preferences and travel plans.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and SFDA review.
• Logistics. Validated cold-chain shipment to your prescribing hospital.
• Concierge case lead. A named point of contact coordinating monthly refills.

What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. See our trust and compliance page.

Is Kesimpta truly self-administered at home? Yes — after the first observed injection and patient training, subsequent monthly doses are self-administered using the Sensoready prefilled pen. Your neurologist confirms patient suitability.

How does Kesimpta compare with Ocrevus or Briumvi? All three are anti-CD20 therapies. Kesimpta is monthly subcutaneous; Ocrevus is six-monthly IV; Briumvi is IV with shorter infusion times. Your neurologist selects based on disease activity, logistics, and patient preference.

Why hepatitis B screening? Anti-CD20 therapy can reactivate latent hepatitis B, so pre-treatment screening is mandatory under FDA labeling.

Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Kesimpta coordination in Saudi Arabia.

Add me to the Kesimpta waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-24.